Times are shown in your local time zone GMT
Ad-blocker Detected - Your browser has an ad-blocker enabled, please disable it to ensure your attendance is not impacted, such as CPD tracking (if relevant). For technical help, contact Support.
Prof Jaishri Blakeley
Johns Hopkins Comprehensive Neurofibromatosis Center
Featured
Professional Bio
Professor of Neurology, Oncology and Neurosurgery Neuro-Oncology
Dr Jaishri Blakeley is a clinician scientist with research expertise in the development of clinical trials for nervous system tumours and specifically, early clinical-translational studies including tumour pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumours and incorporation of patient-focused, functional endpoints into efficacy studies.
In 2012 she cofounded the Neurofibromatosis Therapeutic Acceleration Program (NTAP) to shift the landscape of NF1 clinical care via necessary, efficient and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas.
Through NTAP, Dr Blakeley has supported and collaborated with more than 85 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1 associated neoplasms. The results have been a transformation of the research landscape for both plexiform and cutaneous neurofibromas, including contribution to the development of MEK inhibitors for NF1 tumours. In addition, NTAP facilitates a culture of team science that maximizes the value of each investigation and contributor. Dr. Blakeley’s research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis and primary brain cancer for whom she is honored to provide care
Dr Jaishri Blakeley is a clinician scientist with research expertise in the development of clinical trials for nervous system tumours and specifically, early clinical-translational studies including tumour pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumours and incorporation of patient-focused, functional endpoints into efficacy studies.
In 2012 she cofounded the Neurofibromatosis Therapeutic Acceleration Program (NTAP) to shift the landscape of NF1 clinical care via necessary, efficient and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas.
Through NTAP, Dr Blakeley has supported and collaborated with more than 85 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1 associated neoplasms. The results have been a transformation of the research landscape for both plexiform and cutaneous neurofibromas, including contribution to the development of MEK inhibitors for NF1 tumours. In addition, NTAP facilitates a culture of team science that maximizes the value of each investigation and contributor. Dr. Blakeley’s research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis and primary brain cancer for whom she is honored to provide care